(Q36482412)

14 August 2017

Diffusion disk susceptibility testing with cefotaxime (English)

1 reference

PMC publication ID

352814

https://api.crossref.org/works/10.1128/AAC.16.2.164

14 August 2017

Diffusion Disk Susceptibility Testing with Cefotaxime (English)

1 reference

28 November 2022

1 reference

https://api.crossref.org/works/10.1128/AAC.16.2.164

28 November 2022

author name string

N. Aswapokee

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A114106

28 November 2022

P. Aswapokee

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A114106

28 November 2022

H. C. Neu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A114106

28 November 2022

K. P. Fu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A114106

28 November 2022

language of work or name

English

0 references

publication date

1 August 1979

1 reference

full work available at URL

14 August 2017

3

1 reference

based on heuristic

inferred from page(s)

https://europepmc.org/articles/PMC352814

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A114106

https://europepmc.org/articles/PMC352814?pdf=render

28 November 2022

file format

Portable Document Format

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A114106

https://journals.asm.org/doi/pdf/10.1128/AAC.16.2.164

28 November 2022

1 reference

https://api.crossref.org/works/10.1128/AAC.16.2.164

Antimicrobial Agents and Chemotherapy

28 November 2022

published in

1 reference

14 August 2017

16

1 reference

14 August 2017

2

1 reference

14 August 2017

164-166

1 reference

Comparison of the in vitro activities of HR756 with cephalothin, cefoxitin, and cefamandole

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=352814

HR 756, a New Cephalosporin Active Against Gram-Positive and Gram-Negative Aerobic and Anaerobic Bacteria

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=352814

Activity of HR 756 against Haemophilus influenzae, Barteroides fragilis and Gram-negative rods

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=352814

Cefotaxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitro

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=352814

Beta-Lactamase Stability of HR 756, a Novel Cephalosporin, Compared to That of Cefuroxime and Cefoxitin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=352814

30 September 2017

Identifiers

DOI

10.1128/AAC.16.2.164

1 reference

14 August 2017

1 reference

PMC publication ID

352814

14 August 2017

1 reference

PMC publication ID

352814